Our Proud History
Xenoscience has been a clinical research site since 2001. Founded by Stephen Flitman, MD as an Alzheimer specialty center, Xenoscience expanded into general neurology and advanced pain management. Joshua Tobin, MD joined in 2006 and added expertise in Migraine and atypical headache. We have been involved in over 200 clinical trials and have contributed to the approvals of many drugs.
These are the treatments which Xenoscience has helped to develop over the years which were eventually approved by the US Food and Drug Administration (FDA). Most have also been approved by the EU equivalent agency, European Medicines Agency.
Treatments for Alzheimer's Disease
- Aduhelm
- Aricept
- Axona
- Exelon
- Exelon Patch
- Razadyne
- Razadyne ER
Treatments for Epilepsy
- Aptiom
- Briviact
- Fycompa
- Keppra IV
- Oxtellar XR
- Vimpat
- Xcopri
Treatments for Fibromyalgia
- Cymbalta
- Savella
Treatments for Migraine
- Emgality
- Pediatric Maxalt MLT
- Reyvow
- Ubrelvy
Treatments for Multiple Sclerosis
- Aubagio
- Gilenya
- Ocrevus
- Plegridy
- Tecfidera
- Vumerity
- Zeposia
Treatments for Neuropathic Pain
- Lyrica for Diabetic Neuropathy Pain
- Qutenza for HIV Neuropathy Pain
Treatments for Parkinson's Disease
- Nourianz to improve motor function
- Stalevo to improve motor function
A sobering thought: For every drug that is successfully brought to the US market, many more (sometimes as many as hundreds more) have failed in clinical trials.
